CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: September 16, 2020
Result type: Reports
Project Number: SR0648-000
Product Line: Common Drug Review

Generic Name: etonogestrel

Brand Name: Nexplanon

Manufacturer: Merck Canada Inc.

Indications: Prevention of pregnancy

Manufacturer Requested Reimbursement Criteria1: Indicated for the prevention of pregnancy for up to 3 years

Submission Type: New

Project Status: Active

Companion Diagnostics: No

Fee Schedule: Schedule A

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient input openMay 06, 2020
Call for patient input closedJune 25, 2020

- No patient input submission received

Submission receivedJune 03, 2020

Submission was previously withdrawn and has been refiled by the sponsor

Submission acceptedJune 17, 2020
Review initiatedJune 18, 2020
Draft CADTH review report(s) provided to sponsor for commentJuly 31, 2020
Deadline for sponsors commentsAugust 12, 2020
CADTH responses on draft review report(s) provided to sponsorSeptember 03, 2020
Expert committee meeting (initial)September 16, 2020
Draft recommendation issuedSeptember 28, 2020
September 30, 2020